menu search

Cryptocurrency options trading explained

Cryptocurrency options trading explained Diving deep into the crypto asset landscape reveals a dynamic world of options contracts. On crypto exchange ...

October 24, 2023, 8:46 am

Why is ascent solar technologies (asti) stock up 51% today?

Ascent Solar Technologies (NASDAQ: ASTI ) stock is taking off on Tuesday following a funding recommendation from the Department of Energy (DOE). The ...

October 24, 2023, 8:10 am

Arbutus to report third quarter 2023 financial results and provide corporate update

WARMINSTER, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage...

October 24, 2023, 7:30 am

Avient corporation: long-term prospects remain encouraging despite risks

Revenues remain stagnant as the company has focused more on improved profitability. The company remains profitable despite recent margin volatility. I...

October 24, 2023, 2:16 am

L'oreal: encouraging growth across consumer products division

L'Oréal has seen strong growth in its Consumer Products division, with like-for-like sales increasing by 13.4% in Q3 2023. The division was boosted b...

October 23, 2023, 9:02 pm

Ambrx biopharma: potential with recently released prostate cancer data

Ambrx Biopharma Inc. updated data of ARX517 for the treatment of patients with mCRPC shows encouraging ...

October 23, 2023, 6:50 pm

Sirius real estate rating encouraging in current environment, says broker

Sirius Real Estate's continued receipt of a BBB  rating from agency Fitch is encouraging especially i...

October 23, 2023, 10:01 am

Mastercard's masterstroke: leveraging ai to reduce payment problems

In the ever-evolving world of global payments, Mastercard isn't just going with the flow; they're orchestrating it with the power of AI. Mastercard an...

October 23, 2023, 9:25 am

Encouraging preliminary data from a phase 2 trial evaluating io102-io103 in combination with pembrolizumab for first-line treatment of patients with non-small cell lung cancer and squamous cell carcin

NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating...

October 23, 2023, 5:00 am

Encouraging preliminary data from a phase 2 trial evaluating io102-io103 in combination with pembrolizumab for first-line treatment of patients with non-small cell lung cancer and squamous cell carcin

NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating...

October 23, 2023, 5:00 am

Encouraging preliminary data from a phase 2 trial evaluating io102-io103 in combination with pembrolizumab for first-line treatment of patients with non-small cell lung cancer and squamous cell carcin

NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating...

October 23, 2023, 5:00 am

Encouraging preliminary data from a phase 2 trial evaluating io102-io103 in combination with pembrolizumab for first-line treatment of patients with non-small cell lung cancer and squamous cell carcin

NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating...

October 23, 2023, 5:00 am

Encouraging preliminary data from a phase 2 trial evaluating io102-io103 in combination with pembrolizumab for first-line treatment of patients with non-small cell lung cancer and squamous cell carcin

NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating...

October 23, 2023, 5:00 am

Sutro biopharma announces presentation of data for luveltamab tazevibulin (luvelta) from the phase 1 dose-expansion study in endometrial cancers at esmo 2023

– Luvelta demonstrated encouraging preliminary anti-tumor activity (29% response rate) in late-stage ...

October 22, 2023, 8:25 am

Boyd gaming corporation: leveraging a digital expansion

Boyd Gaming's digital expansion taps into a burgeoning online casino market. Q3 earnings are expected to rise due to heightened summer vacation activi...

October 22, 2023, 4:02 am

Libtayo® (cemiplimab) neoadjuvant treatment demonstrates encouraging event-free survival in patients with resectable cutaneous squamous cell carcinoma (cscc)

89% estimated event-free survival at one year among patients with stage II to IV resectable CSCC who received Libtayo prior to surgery in a Phase 2 tr...

October 21, 2023, 12:48 pm

Wolverine's (www) strategic growth efforts appear encouraging

Wolverine (WWW) has been progressing well on its strategic initiatives. The company also reinforces its presence in the international markets....

October 20, 2023, 1:32 pm

Steven madden's (shoo) strategic growth efforts progress well

Steven Madden's (SHOO) e-commerce business appears encouraging. The company has ramped up digital marke...

October 20, 2023, 1:32 pm

Csx ceo joe hinrichs on earnings and consumer: we're seeing 'encouraging' start to current quarter

Joe Hinrichs, CSX CEO, joins CNBC's "Squawk on the Street" to discuss the rail company's third-quarter earnings....

October 20, 2023, 11:20 am

Boe's bailey says expects a 'marked fall' in inflation next month

September inflation figures not far off what we were expectingCore inflation fell slightly from what we expected, that is quite encou...

October 20, 2023, 5:56 am


Search within

Pages Search Results: